Axoltis Pharma
Gilles Avenard currently serves as the CEO of Acticor Biotech since October 2014 and is the Owner and CEO of Gilles Avenard Biotech Consulting (GABC) since August 2010. Additional roles include Board Member at Axoltis Pharma and Gour Medical SA, as well as a member of the Strategic Committee at SeaBeLife Biotech. Avenard also held the position of CEO for G1J-IdF Venture Fund until June 2022 and has been a Board Member for various companies including Clevexel Pharma, InnaVirVax, and Biophytis. Avenard was the Managing Partner at Alliance4Growth from November 2011 to October 2013. Avenard earned a Medical Doctor degree in Medicine from Université Paris Cité between 1968 and 1976.
This person is not in the org chart
This person is not in any teams
Axoltis Pharma
Axoltis pharma is a biopharmaceutical company dedicated to develop a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs. Our innovative approach: combining Preventative, Neuroprotective, Regenerative & Remodeling properties in a single drug, as the key to cure complex neurological disorders. Our products are first-in-class multifunctional peptides with high potential in many CNS disorders.